Rituximab in rheumatoid arthritis and the risk of malignancies: Report from a French cohort
Author:
Publisher
Elsevier BV
Subject
Rheumatology
Reference23 articles.
1. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation;Colombat;Blood,2001
2. Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analysis with extended follow-up (F/up) of 7 years;Colombat;Blood,2006
3. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis;Edwards;N Engl J Med,2004
4. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial;Emery;Arthritis Rheum,2006
5. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks;Cohen;Arthritis Rheum,2006
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Malignancies and rheumatoid arthritis, csDMARDs, biological DMARDs, and JAK inhibitors: challenge and outlook;Expert Review of Clinical Immunology;2023-08-14
2. Repurposing Drugs: A New Paradigm and Hopes for Life-threatening Diseases;Drug Repurposing Against SARS-CoV-2;2023-04-12
3. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study;Annals of the Rheumatic Diseases;2023-03-03
4. MALİGNİTE VE PRİMER SJÖGREN SENDROMU ARASINDAKİ İLİŞKİ; TEK MERKEZ SONUÇLARI;Acta Medica Nicomedia;2022-06-27
5. Risk of cancer after initiation of targeted therapies in patients with rheumatoid arthritis and a prior cancer: systematic review with meta‐analysis;Arthritis Care & Research;2021-09-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3